These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A study on C-erbB2, nm23 and p53 expressions in epithelial ovarian cancer and their clinical significance].
    Author: Liu L, Yang K.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):101-4. PubMed ID: 11263193.
    Abstract:
    OBJECTIVE: To investigate the expressions of C-erbB2, nm23 and p53 in epithelial ovarian cancer and their clinical significance. METHODS: Expression of C-erbB2, nm23 and p53 proteins was retrospectively studied by immunohistochemistry, and Kaplan-Meier Method and Cox's proportional hazard regression model were used to analyze the relationship of their expressions with prognosis. RESULTS: (1) The expression rate of C-erbB2 was 31.4%, and was in connection with clinical stage. (2) The expression rate of nm23 was 38.6%, while it maybe correlated with pelvic lymph node metastasis. (3) The expression rate of p53 was 34.3%, and the rate was higher in serous ovarian cancer than in mucinous. (4) There was no correlation among the expression of the three proteins. (5) Survival follow-up data showed that mean survival time was shorter in patients with C-erbB2 expression than those without; and nm23 and p53 were not significantly related to survival time. Multivariate Cox's proportional hazard regression model analysis suggest that C-erbB2 expression clinical stage and residual tumor size were three variates significantly contributing to patients prognosis. CONCLUSIONS: C-erbB2 expression has a close relationship with malignancy degree of epithelial ovarian cancer, and significantly contributes to prognosis. p53 expression correlates with its subtype and nm23 with its status of pelvic lymph node metastasis, however, neither contributes to prognosis.
    [Abstract] [Full Text] [Related] [New Search]